David Cella

Midwestern University (US)

Research Areas

Discover Papers by David Cella

Access 250+ million papers and cite this researcher's work with AI assistance

Try AnswerThis Free →

H-index

183

Publications

1912

Citations

145912

i10-index

980

Publications & Citations Over Time

Top Cited Publications

Want to find and read papers by this researcher? AnswerThis gives you instant access.

Title	Year	Citations
The Functional Assessment of Cancer Therapy scale:...	1993	5847
The Patient-Reported Outcomes Measurement Informat...	2010	4743
Interpreting the Clinical Importance of Treatment ...	2007	3177
Paclitaxel plus Bevacizumab versus Paclitaxel Alon...	2007	3023
The Patient-Reported Outcomes Measurement Informat...	2007	2992
Efficacy of Gefitinib, an Inhibitor of the Epiderm...	2003	2523
Recommended methods for determining responsiveness...	2007	2219
Item Banks for Measuring Emotional Distress From t...	2011	2004
Measuring fatigue and other anemia-related symptom...	1997	1906
Pazopanib versus Sunitinib in Metastatic Renal-Cel...	2013	1882

Publications

1.
The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.
Year: 1993Citations: 5847DOI: 10.1200/jco.1993.11.3.570
2.
The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008
Year: 2010Citations: 4743DOI: 10.1016/j.jclinepi.2010.04.011
3.
Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations
Year: 2007Citations: 3177DOI: 10.1016/j.jpain.2007.09.005
4.
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Year: 2007Citations: 3023DOI: 10.1056/nejmoa072113
5.
The Patient-Reported Outcomes Measurement Information System (PROMIS)
Year: 2007Citations: 2992DOI: 10.1097/01.mlr.0000258615.42478.55
6.
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
Year: 2003Citations: 2523DOI: 10.1001/jama.290.16.2149
7.
Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes
Year: 2007Citations: 2219DOI: 10.1016/j.jclinepi.2007.03.012
8.
Item Banks for Measuring Emotional Distress From the Patient-Reported Outcomes Measurement Information System (PROMIS®): Depression, Anxiety, and Anger
Year: 2011Citations: 2004DOI: 10.1177/1073191111411667
9.
Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system
Year: 1997Citations: 1906DOI: 10.1016/s0885-3924(96)00274-6
10.
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Year: 2013Citations: 1882DOI: 10.1056/nejmoa1303989

About David Cella

David Cella is a researcher with 1912 publications and 145912 citations. They are affiliated with Midwestern University. Their research focuses on . With an h-index of 183, they are among the top researchers in their field.

Citation Distribution

Distribution of citations across publications

Research Smarter

AnswerThis uses AI to help you search, understand, and cite research from David Cella and 250M+ other papers.

AI-powered research assistance
Automatic citations and references
Advanced academic writing tools

Research Area Breakdown

Publication Types

Publication type data not available

Impact Metrics Over Time

Citations per publication by year